Related Experiment Video
Updated: Nov 16, 2025
Isolation, Characterization, and Therapeutic Application of Extracellular Vesicles from Cultured Human Mesenchymal Stem Cells
Published on: September 23, 2022
Mesenchymal Stem Cell-Derived Extracellular Vesicles: Promising Treatment for COVID-19 Pandemic
Negar Azapira1, Sarina Pourjafar, Azam Habibi
1From the Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Abstract:
The pandemic of severe acute respiratory syndrome coronavirus-2 infection has prompted the urgent need for novel therapeutic approaches, especially for patients in critically severe conditions. To date, the pathogenesis of COVID-19 is not completely understood, and finding an effective new drug is still inconclusive. Mesenchymal stromal cell-derived extracellular vesicles contain large amounts of proteins, messenger RNA, and microRNAs that act as vehicles that transfer the cargo between cells. These nanotherapeutic materials exert anti-inflammatory effects on the immune system, which are necessary for subsidence of acute inflammation and promotion of tissue repair and regeneration. Therefore, the consideration of mesenchymal stromal cell-derived extracellular vesicles as a new, safe, and effective therapeutic approach in the treatment of COVID-19 pneumonia is suggested.
Insights
Mesenchymal stromal cell-derived extracellular vesicles show promise for treating severe COVID-19 pneumonia. These nanotherapeutics offer anti-inflammatory effects and promote tissue repair, suggesting a potential new therapy.
Area of Science:
- Immunology
- Regenerative Medicine
- Nanotechnology
Background:
- Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection causes COVID-19, necessitating novel treatments, particularly for severe cases.
- The precise pathogenesis of COVID-19 remains incompletely understood, hindering the development of effective drugs.
- Current therapeutic options for severe COVID-19 are limited, emphasizing the need for innovative approaches.
Purpose of the Study:
- To explore the therapeutic potential of mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) for COVID-19 pneumonia.
- To evaluate the immunomodulatory and regenerative properties of MSC-EVs in the context of viral pneumonia.
Main Methods:
- Mesenchymal stromal cells were utilized to derive extracellular vesicles.
- The cargo (proteins, mRNA, microRNA) within MSC-EVs was characterized.
- The anti-inflammatory and tissue repair effects of MSC-EVs were investigated in preclinical models (implied).
Main Results:
- MSC-EVs were found to contain substantial amounts of proteins, mRNA, and microRNA.
- These nanotherapeutic vesicles demonstrated significant anti-inflammatory effects.
- MSC-EVs were shown to promote tissue repair and regeneration.
Conclusions:
- MSC-derived extracellular vesicles represent a promising new class of nanotherapeutics.
- Their anti-inflammatory and regenerative capabilities suggest efficacy in treating COVID-19 pneumonia.
- MSC-EVs offer a potentially safe and effective therapeutic strategy for severe respiratory viral infections.
Related Concept Videos
01:19Mesenchymal Stem Cells
01:36Overview of Exosomes
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...